Molecular therapy: methods&clinical development:癌症科学家的目标,利用蛋白质的力量来阻止肿瘤的生长

2020-04-13 lauren 转化医学网

导言:癌症是威胁人类健康的重大疾病,因此对于肿瘤与机体之间相互作用的研究及新型抗癌药物的开发具有极大的学术和社会价值。肿瘤的发生发展与肿瘤微环境密切相关,细胞因子是肿瘤微环境的重要组成部分,因此研究不

导言:癌症是威胁人类健康的重大疾病,因此对于肿瘤与机体之间相互作用的研究及新型抗癌药物的开发具有极大的学术和社会价值。肿瘤的发生发展与肿瘤微环境密切相关,细胞因子是肿瘤微环境的重要组成部分,因此研究不同细胞因子在肿瘤免疫中的作用具有重大的意义。

2018年,美国约有32.4万人死于癌症。肺癌、前列腺癌和结肠直肠癌的死亡人数占总死亡人数的一半。

如果及早发现,这些癌症中有很大一部分是可以预防或治疗的。现在普渡大学(Purdue Univeisity)的科学家们发明了一种新的治疗方法,可能有助于阻止某些癌症的肿瘤生长,比如前列腺癌,这是男性最常见的癌症类型之一。

“我们已经设计了一个治疗模式,可以帮助招募免疫细胞杀死癌细胞,也帮助修复骨和肿瘤组织受损,”美国普渡大学兽医学院基本医疗科学副教授Marxa Figueiredo说,Marxa Figueiredo曾帮助领导这个研究团队,并正在与普渡大学研究基金会技术商业化办公室专利合作,为这项创新申请专利。

“这项技术最好的特点之一是,它在许多其他癌症和疾病的治疗上显示出巨大的潜力,这些癌症和疾病可以从阻止肿瘤生长和促进骨骼修复中获益。”

该治疗技术发表在《分子治疗:方法与临床发展》杂志上。

普渡大学的研究小组使用了一种名为白细胞介素-27或IL-27的蛋白质,这种蛋白质在减少肿瘤生长和帮助阻止癌症在体内扩散方面显示出了希望。IL-27是一种细胞因子,是免疫系统细胞分泌的一种蛋白质,起化学信使的作用,可以帮助免疫系统对抗癌症和其他疾病。

研究人员已经检测了一种新的靶向细胞因子,白细胞介素27 (IL-27)在C端的作用,它具有双重靶向性和治疗性七肽,可以用于治疗前列腺癌。IL-27已经在几种癌症模型中显示了抑制肿瘤生长和调节肿瘤消退的希望,其中就包括前列腺癌。研究人员描述了关于靶向IL-27基因在体外和体内对前列腺癌细胞的影响,以及靶向如何增强IL-27细胞因子的生物活性。我们采用了IL-27基因传递方案,利用超声传递(sonodelivery),目的是在免疫增强的TC2R C57/BL6模型中减少前列腺肿瘤生长。

研究小组和其他研究人员先前已经证实,细胞因子白细胞介素-27 (IL-27)是一种有前途的细胞因子,基于其多功能(免疫刺激,抗血管生成,成骨性)活动,能够治疗关节炎和恶性肿瘤。例如,IL-27有助于防止破骨细胞的形成,是促进成骨细胞分化、骨转移性肿瘤的关键治疗特征。因此,IL-27的体内基因传递显著降低了肿瘤生长速度和骨常态化。

Figueiredo说:“免疫细胞很自然地会被身体的某些区域所吸引,这些区域有许多来自蛋白质(如IL-27)的信号。”“我们的新方法是针对IL-27肿瘤或骨细胞,我们可以使用这些蛋白质产生信号,将身体的健康细胞带到患有癌症或其他疾病身体区域,杀死肿瘤,并开始修复骨和其他肌肉骨骼组织。”

Figueiredo说,这项新的普渡大学治疗技术可以应用于患有多种不同类型癌症的人和动物,包括乳腺癌和肺癌,以及其他蛋白质靶向可以改善免疫系统反应的疾病。

原始出处:

M.L.Figueiredo, M.Figueiredo Neto, J.W.Salameh, et.al. Ligand-mediated targeting of cytokine Interleukin-27 enhances its bioactivity in vivo. Molecular Therapy - Methods & Clinical Development Available online 30 March 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739012, encodeId=7d311e3901239, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sat Jul 04 16:06:22 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896637, encodeId=9cce189663edc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 16:06:22 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982326, encodeId=168a198232609, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jun 24 07:06:22 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765826, encodeId=5d191e658262d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 23 08:06:22 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297110, encodeId=1132129e110f1, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507718, encodeId=03c2150e718e9, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739012, encodeId=7d311e3901239, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sat Jul 04 16:06:22 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896637, encodeId=9cce189663edc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 16:06:22 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982326, encodeId=168a198232609, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jun 24 07:06:22 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765826, encodeId=5d191e658262d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 23 08:06:22 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297110, encodeId=1132129e110f1, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507718, encodeId=03c2150e718e9, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-05-13 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739012, encodeId=7d311e3901239, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sat Jul 04 16:06:22 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896637, encodeId=9cce189663edc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 16:06:22 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982326, encodeId=168a198232609, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jun 24 07:06:22 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765826, encodeId=5d191e658262d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 23 08:06:22 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297110, encodeId=1132129e110f1, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507718, encodeId=03c2150e718e9, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-06-24 fzwish20000
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739012, encodeId=7d311e3901239, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sat Jul 04 16:06:22 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896637, encodeId=9cce189663edc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 16:06:22 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982326, encodeId=168a198232609, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jun 24 07:06:22 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765826, encodeId=5d191e658262d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 23 08:06:22 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297110, encodeId=1132129e110f1, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507718, encodeId=03c2150e718e9, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1739012, encodeId=7d311e3901239, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sat Jul 04 16:06:22 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896637, encodeId=9cce189663edc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 16:06:22 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982326, encodeId=168a198232609, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jun 24 07:06:22 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765826, encodeId=5d191e658262d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 23 08:06:22 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297110, encodeId=1132129e110f1, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507718, encodeId=03c2150e718e9, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1739012, encodeId=7d311e3901239, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sat Jul 04 16:06:22 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896637, encodeId=9cce189663edc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 16:06:22 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982326, encodeId=168a198232609, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jun 24 07:06:22 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765826, encodeId=5d191e658262d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Jan 23 08:06:22 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297110, encodeId=1132129e110f1, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507718, encodeId=03c2150e718e9, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Wed Apr 15 03:06:22 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-04-15 zll0628

相关资讯

盘点:2020年度J Clin Oncol杂志回顾汇总(三)

J Clin Oncol:2020年ASCO临床肿瘤学年度进展报告

J Immunother Cancer:营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

该研究表明,中药复方苦参注射液通过TNFR1解除肿瘤免疫微环境中的肿瘤相关巨噬细胞(TAMs)引起的免疫抑制,从而增敏低剂量索拉菲尼的肝癌治疗效果,为肝癌的临床治疗提供了新策略。

PNAS:肿瘤发生过程中的肠道宿主-微生物平衡调控

在所有动物体内,肠道上皮形成了一道严密的环境屏障。肠上皮调节营养物质的吸收、免疫反应,并防止全身感染。

JAMA Oncol:谢丛华教授发现肿瘤患者感染新冠病毒的风险是普通人群的2.31倍

3月25日,国际医学期刊《JAMA Oncology》在线发表了由武汉大学中南医院肿瘤放化疗科谢丛华教授及团队针对肿瘤患者新冠肺炎感染风险的一篇文章

Nature:全新发现一种重要的癌症免疫治疗新方法:Gasdermin E

近期来自波士顿儿童医院发现了癌症免疫疗法的另外一种新武器,可以在更多的癌症类型中发挥作用。这种方法利用人体内免疫反应重新激活称为Gasdermin E的基因,这种基因在许多类型的癌症中均被抑制。

Cell Death Dis:核糖体成熟因子SBDS双重调控p53

SBDS基因,因与Shwachman-Bodian Diamond综合征(SBDS)高度相关而得名。该综合征的主要特征为胰腺功能障碍、血液循环系统衰竭、骨骼畸形及神经系统相关表型。SBDS基因能够参与

拓展阅读

Nature:突破性癌症治疗:RMC-7977的活性状态RAS抑制作用

这些研究结果为未来的癌症治疗提供了重要的基础,特别是对于那些传统治疗方法效果不佳的KRAS突变癌症患者。随着更多的临床数据的积累,RMC-7977的应用前景将进一步明朗化。

大至8.9厘米的肿瘤不能手术怎么办?冷冻治疗仅需半小时,患者当天可回家

尽管乳腺癌可以比较早期的发现,但是仍然有很多的患者发现罹患乳腺癌的时候面临治疗困境,假设肿瘤可以通过手术治疗,但是有很多人因为各种原因不能进行手术,比如肿瘤比较大的情况,手术就不是很理想的治疗方式。

Nat Cancer:中山大学张弩等团队合作揭示苏氨酸代谢驱动肿瘤异常tRNA修饰和蛋白翻译

该研究发现苏氨酸通过YRDC介导的密码子偏倚翻译重编程为胶质母细胞瘤提供燃料。该研究发现胶质母细胞瘤干细胞(GSCs)显示出升高的蛋白质翻译。

张连兵教授/程根阳教授​团队: 享受日光浴的好处——低剂量蓝光照射皮肤激活天然免疫力,可抑制肿瘤生长和转移

研究发现使用450 nm的低剂量蓝光照射皮肤,能够通过增加细胞内源性活性氧簇(ROS),可无创快速激活机体天然免疫力,甚至可以抑制肿瘤生长和转移。

领跑肿瘤新前沿|一周热点大分享!

肿瘤学热点一网打尽!深入解读权威指南,分享最受欢迎的治疗公式,为您的临床决策提供有力支持。不容错过的肿瘤治疗新知识,尽在这理,点击立即查看!

肿瘤标志物常用单位换算

肿瘤标志物常用单位换算